Clinical Trial

Johnson & Johnson unveils three-year Tremfya data for Crohn's disease, highlighting bold fistula results and framing a new battle over trial reporting.

A new monoclonal antibody targeting the root cause of Graves' and thyroid eye disease could upend a market dominated by cumbersome infusions.

Basel-based biotech Nouscom just raised €120 million to fund a pivotal trial for NOUS-209, shifting oncology from treating tumors to intercepting them entirely.

Cyrano Therapeutics reports positive Phase 2 data for a repurposed asthma drug to treat post-viral smell loss, but regulatory hurdles loom for Phase 3.

As Jasper Therapeutics completes Phase 2 enrollment for its novel IgAN therapy, we examine the structural shifts reshaping rare kidney disease treatment.

An N-of-3 pilot study reveals how Krystal Biotech's new intratumoral immunotherapy could replace lifelong surgeries with systemic immune clearance.

Merz completes Phase III migraine trial recruitment six months early, signaling a strategic threat to AbbVie’s dominance with its purified neurotoxin, XEOMIN.

Phanes Therapeutics has advanced its first-in-class bispecific antibody into colorectal cancer trials, testing a novel mechanism to bypass systemic toxicity.

By halving infusion volumes for immunodeficiency patients, Takeda's experimental TAK-881 is not just treating a disease—it is giving people their time back.

Pilatus Biosciences doses its first Hong Kong patient with PLT012, signaling a strategic shift toward metabolic immunotherapies and Asian clinical hubs.

Parabilis Medicines advances its first-in-class beta-catenin inhibitor into a new FAP cohort, signaling a paradigm shift from surgical intervention to systemic prevention.

Orum Therapeutics enters the clinic with a novel degrader-antibody conjugate, aiming to turn a historically toxic mechanism into a targeted lifeline for AML.

As Novastra Therapeutics prepares to unveil Phase 1 data at ESMO, its supramolecular nanocloak could redefine how we treat checkpoint-resistant solid tumors.

Immuron’s Phase 2 Travelan trial missed its primary endpoint, but a 71% drop in antibiotic use has the Pentagon and microbiome experts paying close attention.

After a high-profile Phase 2 trial failure in pulmonary fibrosis, Syndax narrows its strategic focus to maximize its established cGVHD partnership with Incyte.

New real-world data reveals a 34% drop in hospitalizations for heart failure patients using CCM therapy, bridging a crucial gap in cardiac care economics.

By proving IBSRELA reduces costly specialist visits, Ardelyx is arming itself for payer negotiations and a lucrative leap into the broader constipation market.

Odyssey Therapeutics is testing a novel combination therapy for ulcerative colitis, aiming to break the therapeutic ceiling that limits current IBD treatments.

By targeting the genetic roots of BAG3 cardiomyopathy with a novel low-dose capsid, Affinia aims to solve gene therapy’s systemic toxicity bottleneck.

For decades, severe acne treatments forced patients into a maze of antibiotics and harsh side effects. A new drug might finally change the system.